DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 205435
NDA 205435 describes SIVEXTRO, which is a drug marketed by Cubist Pharms Llc and is included in two NDAs. It is available from one supplier. There are three patents protecting this drug. Additional details are available on the SIVEXTRO profile page.
The generic ingredient in SIVEXTRO is tedizolid phosphate. One supplier is listed for this compound. Additional details are available on the tedizolid phosphate profile page.
The generic ingredient in SIVEXTRO is tedizolid phosphate. One supplier is listed for this compound. Additional details are available on the tedizolid phosphate profile page.
Summary for 205435
| Tradename: | SIVEXTRO |
| Applicant: | Cubist Pharms Llc |
| Ingredient: | tedizolid phosphate |
| Patents: | 3 |
Pharmacology for NDA: 205435
| Ingredient-type | Oxazolidinones |
| Mechanism of Action | Breast Cancer Resistance Protein Inhibitors |
Suppliers and Packaging for NDA: 205435
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435 | NDA | Merck Sharp & Dohme Corp. | 67919-041 | N | 67919-041-01 |
| SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435 | NDA | Merck Sharp & Dohme Corp. | 67919-041 | N | 67919-041-02 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 200MG | ||||
| Approval Date: | Jun 20, 2014 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Jun 20, 2024 | ||||||||
| Regulatory Exclusivity Use: | GENERATING ANTIBIOTIC INCENTIVES NOW | ||||||||
| Regulatory Exclusivity Expiration: | Jun 20, 2019 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | ➤ Sign Up | Patent Expiration: | Feb 23, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patented Use: | METHOD OF TREATING BACTERIAL INFECTIONS | ||||||||
Complete Access Available with Subscription
